Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin

Antimicrob Agents Chemother. 1999 Jul;43(7):1754-5. doi: 10.1128/AAC.43.7.1754.

Abstract

The rabbit model of endocarditis was used to test the effectiveness of vancomycin and two different lysostaphin dosing regimens for the treatment of infections caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin (glycopeptide-intermediate susceptible S. aureus [GISA]). Vancomycin was ineffective, with no evidence of sterilization of aortic valve vegetations. However, rates of sterilization of aortic valve vegetations were significantly better for animals treated with either a single dose of lysostaphin (43%) or lysostaphin given twice daily for 3 days (83%) than for animals treated with vancomycin. Rabbits given a single dose of lysostaphin followed by a 3-day drug-free period had mean reductions in aortic valve vegetation bacterial counts of 7.27 and 6.63 log10 CFU/g compared with those for untreated control rabbits and the vancomycin-treated group, respectively. We conclude that lysostaphin is an effective alternative for the treatment of experimental aortic valve endocarditis caused by a clinical VISA strain.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use*
  • Aortic Valve*
  • Drug Resistance, Microbial
  • Endocarditis, Bacterial / drug therapy*
  • Female
  • Heart Valve Diseases / drug therapy*
  • Lysostaphin / therapeutic use*
  • Rabbits
  • Staphylococcal Infections / drug therapy*
  • Vancomycin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Vancomycin
  • Lysostaphin